PURPOSE: Tissue transglutaminase (TG2) is a multifunctional protein that is implicated in development of drug resistance and metastasis. Therefore, we examined therapeutic targeting of TG2 for inhibiting growth and metastasis of in vivo growing pancreatic ductal adenocarcinoma (PDAC) in nude mice. EXPERIMENTAL DESIGN: We implanted Panc-28 pancreatic cancer cells to induce orthotopic PDAC tumors in nude mice and determined the efficacy of liposomal TG2 small interfering RNA (siRNA) either alone or in combination with gemcitabine. RESULTS: We show that down-regulation of endogenous TG2 by siRNA could effectively block the growth of PDAC. Moreover, down-regulation of TG2 significantly enhanced the therapeutic efficacy of gemcitabine against PDAC and inhibited metastatic spread of the disease. The antitumor activity was related to inhibition of proliferation, angiogenesis, and Akt phosphorylation. CONCLUSION: siRNA-mediated down-regulation of TG2 represents a promising therapeutic approach for improved treatment of PDAC.
PURPOSE:Tissue transglutaminase (TG2) is a multifunctional protein that is implicated in development of drug resistance and metastasis. Therefore, we examined therapeutic targeting of TG2 for inhibiting growth and metastasis of in vivo growing pancreatic ductal adenocarcinoma (PDAC) in nude mice. EXPERIMENTAL DESIGN: We implanted Panc-28 pancreatic cancer cells to induce orthotopic PDACtumors in nude mice and determined the efficacy of liposomal TG2 small interfering RNA (siRNA) either alone or in combination with gemcitabine. RESULTS: We show that down-regulation of endogenous TG2 by siRNA could effectively block the growth of PDAC. Moreover, down-regulation of TG2 significantly enhanced the therapeutic efficacy of gemcitabine against PDAC and inhibited metastatic spread of the disease. The antitumor activity was related to inhibition of proliferation, angiogenesis, and Akt phosphorylation. CONCLUSION: siRNA-mediated down-regulation of TG2 represents a promising therapeutic approach for improved treatment of PDAC.
Authors: Dong Hoon Shin; Hyo-Jong Lee; Hye-Young Min; Sun Phil Choi; Mi-Sook Lee; Jung Weon Lee; Faye M Johnson; Kapil Mehta; Scott M Lippman; Bonnie S Glisson; Ho-Young Lee Journal: J Natl Cancer Inst Date: 2013-10-03 Impact factor: 13.506
Authors: Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Gautam Sethi; Parmeswaran Diagaradjane; Preetha Anand; Manoj K Pandey; Juri Gelovani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal Journal: Int J Cancer Date: 2010-07-15 Impact factor: 7.396
Authors: Yihui Shi; Khalid Amin; Barbara G Sato; Steven J Samuelsson; Lidia Sambucetti; Zishan A Haroon; Keith Laderoute; Brian J Murphy Journal: Cancer Biol Ther Date: 2010-03-20 Impact factor: 4.742
Authors: Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr Journal: Mol Carcinog Date: 2015-08-10 Impact factor: 4.784